Latest news
Systemic Delivery of Biologics via Inhalation: Overcoming Injection Aversion in Modern Therapies
That was the title of the talk by Dr Orest Lastow, CTO at Iconovo, at the meeting New updates in Drug Formulation & Bioavailability organized by Life Science…
Grundaren av Iconovo, Dr Orest Lastow, om att vara sci-fi-författare
Grundaren av Iconovo, Dr Orest Lastow, har blivit intervjuad av Life Science Sweden om sin nya parallella karriär som sci-fi-författare. Orest kombinerar…
Press releases
Apr 14, 2026, 15:40
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Staff change
Apr 14, 2026, 15:40
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Staff change
Mar 17, 2026, 16:05
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-ext-nq
mfn-ext-nq-listing
Mar 17, 2026, 16:05
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-ext-nq
mfn-ext-nq-listing
Mar 10, 2026, 08:05
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-ext-nq
mfn-ext-nq-listing
Mar 10, 2026, 08:05
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-ext-nq
mfn-ext-nq-listing
Mar 02, 2026, 16:20
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-cus-top-disclaimer
mfn-ext-nq
mfn-ext-nq-listing
Mar 02, 2026, 16:20
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-cus-top-disclaimer
mfn-ext-nq
mfn-ext-nq-listing
Feb 27, 2026, 18:20
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-cus-top-disclaimer
mfn-ext-nq
mfn-ext-nq-listing
Feb 27, 2026, 18:20
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-cus-top-disclaimer
mfn-ext-nq
mfn-ext-nq-listing
Feb 24, 2026, 20:50
News
IR
Swedish
Corporate Action
Other
mfn-ext-nq
mfn-ext-nq-corporate-action
Feb 24, 2026, 20:50
News
IR
English
Corporate Action
Other
mfn-ext-nq
mfn-ext-nq-corporate-action
Feb 13, 2026, 08:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-cus-top-disclaimer
mfn-ext-nq
mfn-ext-nq-listing
Feb 13, 2026, 08:30
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-cus-top-disclaimer
mfn-ext-nq
mfn-ext-nq-listing
Feb 12, 2026, 14:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Action
Prospectus
Feb 12, 2026, 14:30
News
IR
English
Regulatory
Listing Regulation
Corporate Action
Prospectus
Feb 12, 2026, 08:30
News
IR
English
Regulatory
MAR
Report
Interim
Yearend
Feb 12, 2026, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Yearend
Jan 15, 2026, 10:15
News
IR
English
Corporate Action
Other
mfn-ext-nq
mfn-ext-nq-corporate-action
Jan 15, 2026, 10:15
News
IR
Swedish
Corporate Action
Other
mfn-ext-nq
mfn-ext-nq-corporate-action
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
Interim CEO
Anders Månsson
Mail: anders.mansson@iconovo.se